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multiple receptors binding and is dependent on
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Naguib Salleh* and Vivi Noryati AhmadAbstract
Background: Ficus deltoidea, is a perennial herb that is used to assist labor, firm the uterus post-delivery and to
prevent postpartum bleeding. In view of its claimed uterotonic action, the mechanisms underlying plant’s effect on
uterine contraction were investigated.
Methods: Adult female SD rats were injected with 2 mg/kg 17β-oestradiol (E2) to synchronize their oestrous cycle.
A day after injection, uteri were removed for in-vitro contraction studies. The dose dependent effect of Ficus deltoidea
aqeous extract (FDA) on the tension produced by the isolated rat’s uteri was determined. The effects of atropine
(2×10-8 M), atosiban (0.5 IU), THG113.31 (10 μM), oxodipine (0.25 mM), EDTA (1 mM), 2-amino-ethoxy-diphenylborate
(2-APB) (40 mM) and thapsigargin (1 mM) on the maximum force of contraction (Emax) achieved following 2 mg/ml
FDA administration were also investigated.
Results: FDA induced in-vitro contraction of the isolated rat’s uteri in a dose-dependent manner. Administration of
atropine, atosiban and THG113.31 reduced the Emax with atosiban having the greatest effect. The Emax was also
reduced following oxodipine and EDTA administration. There was no significant change observed following 2-APB
administration. Thapsigargin, however, augmented Emax.
Conclusions: FDA-induced contraction of the isolated rat’s uteri is mediated via multiple uterotonin receptors
(muscarinic, oxytocin and prostaglandin F2α) and was dependent on the extracellular Ca2+. Contraction, however,
was not dependent on the Ca2+ release from the internal stores. This in-vitro study provides the first scientific
evidence on the claimed effect of Ficus Deltoidea on uterine contraction.
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Uterotonic plants, are plants that stimulate uterine con-
traction and have been used since the ancient times to
assist labor, remove the retained placenta, treat post par-
tum bleeding and as an abortifacient [1]. Despite their
use, scientific evidence to substantiate their beneficial effects
are still being explored Several plant extracts have been
reported to induce uterine contraction which include the
leaves extract of P. nigrescens, C. bonduc and A. africanus* Correspondence: naguib.salleh@yahoo.com.my
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distribution, and reproduction in any medium[2-4], roots extract of C. papaya [5,6] and L. pumila [7] and
several other extracts from various plant species [8,9].
One of the plants that is popularly used among the
Southeast Asian women to induce uterine contraction is
Ficus deltoidea, which belongs to the family Moraceae
[10]. Ficus deltoidea has been claimed to possess uterotonic
properties that can assist labor as well as can promote invo-
lution of the uterus, cervix and vagina during the post-
partum period. In addition, it has also been used to treat
abnormalities in the menstrual cycle and for birth spa-
cing purposes. Ficus deltoidea is a small perennial herb
which rarely exceeds 2 meters in height and is domestic-
ally cultivated. It is known by various names such as Masentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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The Philippines and Kangkalibang in Africa [11]. Different
sub-species can be identified based on the leaf shape; with
the female plants possessing larger and more round leaves,
whereas the males are smaller with long and round leaves
[12]. All parts of this plant are medicinally useful. The
leaves (when boiled), stems, roots and fruits are trad-
itionally use to treat arthritis, boost the immune system
and increase the sexual desire [13]. Additionally, the leaves
are also claimed to be a powerful fat burner, help to de-
crease plasma cholesterol level and are experimentally
proven to lower the blood glucose level [14]. Recently,
the fruit extract of Ficus deltoidea was found to possess
antidiabetic and antioxidant properties [15].
The notion that Ficus deltoidea affects uterine con-
traction was based on several previous studies involving
other Ficus species which also indicate their effect on
the uterine contractility. Most of these studies were con-
ducted in-vitro using isolated uteri from rodents. Bafor
et al. [16] conducted an in-vitro study using isolated strips
of mouse uteri to investigate the effect of the active con-
stituent of Ficus exasperata leaf extract on uterine con-
traction. They have found that metabolites generated
from this extract possess both tocolytic and uterotonic
activities. Earlier, in-vitro contraction studies using
isolated rat’s uteri revealed both stimulatory [17] and
inhibitory [18] effects of the unpurified extract of Ficus
exasperata. Further to this, Watcho et al., [1] demon-
strated that fruit extract of Ficus asperifolia stimulates
in-vitro contraction of the uteri isolated from oestro-
genized rats. Another Ficus species, Ficus capensis was
shown to inhibit in-vitro contraction also in the isolated
rat’s uteri [19]. In view of the fact that Ficus species was
found to affect uterine contractility, we hypothesized
that Ficus deltoidea, which is also from the Moraceae
family, may affect uterine contraction as traditionally
claimed. Therefore, using similar experimental model
[1,17,18,20], we investigated Ficus Deltoidea effect on
uterine contraction.
Methods
Preparation of F. Deltoidea Aqeous extract (FDA)
Leaves of F deltoidea from female sub-species used in
this study were supplied by Delto Medicama Plantation,
Kuala Selangor, Malaysia. The plant sample was deposited
at the Herbarium in Rimba Ilmu, University of Malaya,
Kuala Lumpur for authentication and identification pur-
poses with Herbarium number: KLU 46469. The leaves
were air-dried, cut into small pieces and grounded into
powder form. Each of the pulverized parts were weighed
(100 grams) and boiled twice in 1 litre distilled water for
4 hours. The aqueous extract was then concentrated by
heating at 60°C and was later subjected to freeze- drying
(yield 7.36% and 11.61% w/w, dry weight basis for leaf)and was stored in a container until further use. Stock
solution was obtained by dissolving small aliquots of
this extract in water.
Uterine tissue preparation and In-Vitro contraction study
Adult female Wistar Kyoto (WKY) rats weighing 250 grams
were purchased from the Animal House, Faculty of
Medicine, University of Malaya, Kuala Lumpur. The rats
were housed in a controlled environment with temperature
kept at 25°C, relative humidity between 30–70%, 12 hours
light–dark cycle and had free access to rodent food pellet
and tap water ad libitum. Cleanliness of the housing envir-
onment was maintained daily. Shredded recycled paper
was used as bedding. Each group consists of six rats
(n = 6). All experimental procedures were approved by
the University of Malaya Medical Center Animal Ethics
Committee (Ethics Reference No: FIS/ 01/12/2008/ NS (R)).
Intact, non-ovariectomised female WKY rats were treated
with high dose of E2 at 2 mg/kg/day to synchronize their
oestrous cycle [17]. A day after injection, the rats were
humanely sacrificed and the uteri were immediately
removed and placed into a physiological solution. The
tissue was then placed vertically in an organ bath con-
taining solution with the following electrolytes compos-
ition: NaCl (155 mM), KCl (4.5 mM), MgCl2 (1.0 mM),
CaCl2 (2.0 mM) and D- glucose (10 mM) while the pH
was maintain at 7.40 with NaOH. The temperature of the
organ bath was maintained at 37°C. 95% O2 and 5% CO2
was continuously delivered into the bathing solution. Each
uterine strip was placed under optimum resting force of
1 g and was allowed to equilibrate for 30 minutes prior
to drug administration. During this period, the strips
were washed with 10 ml fresh physiological solution
every 15 minutes according to the method by Oropeza
et al., [21]. Each experiment was repeated six times
using new uterine strips from different rats (n = 6). Con-
tractile forces were recorded isometrically by a force
transducer which was connected to a bridge amplifier
and to the PowerLab data acquisition system (ADI
Instrument, Australia).
FDA was added in a dose-dependent manner (0.125-
4.0 mg/ml) and the dose- response effect was then recorded.
Preliminary investigation revealed that 1 × 10-2 M Ach
(Sigma-Aldrich), 7 I.U. oxytocin (Sigma-Aldrich) and
5 μg/ml PGF2α (Sigma-Aldrich) produced maximum
force of contraction (Emax), which values differ between
the respective agonists. Meanwhile, 2 mg/ml FDA also
resulted in maximum contraction (Emax), however
with a lower Emax than other tested agonists. Atropine
(Sigma-Aldrich) (2 × 10-8 M), a muscarinic receptor antag-
onist; atosiban (Fluka Co) (0.5 IU), an oxytocin receptor
antagonist, THG113.31 (Theratechnologies) (10 μg/ml),
a PGF2α receptor antagonist, oxodipine (Sigma-Aldrich)
(0.25 μM), an L-type Ca2+-channel blocker, 2-APB (Sigma
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gargin (Sigma Aldrich) (1 μM), a sarcoplasmic reticulum
Ca2+-ATPase (SERCA) inhibitor and EDTA (Sigma Aldrich)
(1 mM), a Ca2+ chelator were administered to investi-
gate the mechanism underlying FDA effect on uterine
contraction. In order to observe the effect of these
inhibitors, 2 mg/ml FDA was initially added into the
bathing solution and once contraction was stable at
Emax, these inhibitors were either individually or simul-
taneously added and their effects on the Emax were then
recorded.
Statistical analysis
Results were expressed as mean ± SEM. Data was ana-
lyzed using Student’s t- test. p < 0.05 was considered to
be statistically significant.
Results
Dose-dependent effect of FDA on uterine contraction
In Figure 1, the force of contraction increases with in-
creasing doses of FDA. In the control group, the forceFigure 1 The effect of FDA on uterine contraction. (a) Tracing of isometri
and (b) mean tension generated from six isolated uterine horns obtained from
FDA at concentrations ranging between 0.125 to 4 mg/ml. There was a do
The tension recorded following administration of 2 mg/ml FDA was 4.9 timrecorded was 0.5 ± 0.05 g tension, which was the baseline
contraction in oestrogenized rats’ uteri. At 0.25 mg/ml,
the force generated was 2.4 times greater than the con-
trol. Meanwhile, the forces increase by 3.0, 4.1 and 4.9
times following administration of 0.5, 1 and 2 mg/ml
FDA respectively with 2 mg/ml FDA produced the max-
imum tension (Emax).Effect of atropine, THG113.31 and atosiban on the Emax
induced by 2 mg/ml FDA
In Figure 2, administration of muscarinic receptor antagon-
ist, atropine, into the bathing solution containing isolated
uterine tissue pre-exposed to 2 mg/ml FDA resulted in the
Emax to decrease by 1.19 times. Meanwhile, administration
of THG113.31, a non-competitive inhibitor for PGF2α
receptor, as well as atosiban, an oxytocin receptor blocker
resulted in the Emax to also decrease by 1.32 and1.60
times respectively. Simultaneous administration of atropine,
atosiban and THG113.31 resulted in 4.45 times decrease in
Emax as compared to 2 mg/ml FDA administration alone.c uterine contraction following administration of various doses of FDA
different oestrogenized rats, which were exposed to various doses of
se-dependent increase in the tension with increasing doses of FDA.
es higher than the control. n = 6 (* p < 0.05 as compared to control).
Figure 2 The effect of selected receptor antagonists on FDA-induced uterine contraction. (a) Representative tracings of isometric uterine
contraction following FDA administration in the presence of various antagonists and (b) mean Emax following administration of FDA at 2 mg/ml
and in the presence of atropine, THG113.31 and atosiban. Atropine caused the least inhibition while atosiban produced the greatest inhibition on
the Emax. Concomitant administration of all three antagonists resulted in a remarkable decrease in the Emax. n = 6 rats per group, *p < 0.05.
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In Table 1, the relative potency of FDA was compared to
other uterotonins. The Emax produced following admin-
istration of 2 mg/ml FDA was 2.45 ± 0.10 g. Meanwhile,
the Emax produced following administration of 1 × 10-2 M
Ach, 7 I.U oxytocin and 5 μg/ml PGF2α were 2.98 ± 0.25,
3.51 ± 0.47 and 3.43 ± 0.19 g respectively.
Effect of oxodipine and EDTA on the Emax induced by
2 mg/ml FDA
In Figure 3, administration of oxodipine, a voltage-gated
L-type Ca2+ channel antagonist into the bathing solution
containing isolated uterine tissue pre-exposed to 2 mg/ml
FDA resulted in the Emax to decrease by 88.5%. Mean-
while, administration of EDTA into this solution which
resulted in depletion of extracellular Ca2+ caused the Emax
to decrease by a greater percentage (96.8%). Lesser degree
of inhibition by oxodipine and EDTA in isolated uterine
tissue pre-exposed to oxytocin indicated that this effect
of oxytocin was not solely dependent on the extra-
cellular Ca2+.Table 1 Relative potency of FDA as compared to
other uterotonins
Tension (g)
FDA 2.45 ± 0.10
Acetylcoline (Ach) 2.98 ± 0.25
Oxytocin 3.51 ± 0.27
Prostaglandin F2α (PGF2α) 3.43 ± 0.19
FDA is 1.43 times less potent than oxytocin. This extract is also 1.40 and 1.21
times less potent than PGF2α and Ach respectively. n = 6 per treatment group.Effect of 2-APB and thapsigargin on the Emax induced by
2 mg/ml FDA
In Figure 4, administration of 2-APB, an IP3R blocker
into the bathing solution containing isolated uterine
tissue pre-exposed to 2 mg/ml FDA did not cause any
significant changes in the Emax produced. Meanwhile,
administration of SERCA inhibitor, thapsigargin, resulted
in 8.5% increase in the Emax as compared to FDA alone.
2-APB caused a significant decrease in the Emax in iso-
lated uterine tissue pre-exposed to oxytocin, while thapsi-
gargin administration resulted in the opposite effect.
Discussion
To the best of our knowledge, this study is the first to
display uterotonic effect of Ficus deltoidea, which justifies
the claim that this plant assists in uterine contraction. We
have shown that FDA effect is mediated via muscarinic,
oxytocin and PGF2α receptors and is dependent on the
extracellular Ca2+. These mechanisms were confirmed
from inhibition of the maximum tension (Emax) pro-
duced by 2 mg/ml FDA following administration of the
antagonists to these receptors and inhibitors to the Ca2+
channels. FDA is 1.43 times less potent than oxytocin,
which is a gold standard uterotonin [15]. Apart from
Ficus deltoidea, a few other Ficus species including Ficus
exasperata [17,22] and Ficus asperifolia [1] were also re-
ported to stimulate uterine contraction, suggesting that
uterotonic effect is common to the Ficus species.
Our findings suggested that FDA-induced uterine con-
traction was mediated mainly via the oxytocin receptor
as evidenced by the highest degree of inhibition of the
Figure 3 The effect of calcium channel blocker and extracellular calcium removal on FDA-induced uterine contraction. Representative
image of isometric uterine contraction following administration of (a) 2 mg/ml FDA plus oxodipine, (b) oxytocin plus oxodipine, (c) 2 mg/ml
FDA plus EDTA and (d) oxytocin plus EDTA while bar chart shows the Emax following oxodipine and EDTA administration as compared to the
control. Contraction was almost abolished following EDTA administration in the isolated uteri pre-exposed to FDA. n = 6 (* p < 0.05).
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THG113.31 suggested that FDA binding to PGF2α re-
ceptor produced moderate degree of contraction while
the lowest inhibition by atropine suggested that FDA
binding to the muscarinic receptor produced the least
degree of contraction. The cumulative inhibitory effect
observed following concomitant administration of atropine,Figure 4 The effect of IP3R blocker and SERCA inhibitor on FDA-indu
contraction following administration of (a) oxytocin plus 2-APB, (b) FDA 2
plus thapsigargin while bar chart shows the Emax following oxytocin and
thapsigargin. No significant difference was noted following 2-APB adminis
but significant increase in the Emax.THG113.31 and atosiban confirmed the involvement of
all three receptors in mediating FDA-induced uterine
contraction. The presence of muscarinic, oxytocin and
PGF2α receptors in the uterus has been previously re-
ported [23-25]. These receptors were reported to be
up-regulated by E2 and in the late pregnancy particularly
at term [26]. In view of this, high dose E2 administrationced uterine contraction. Representative image of isometric uterine
mg/ml plus 2-APB, (c) oxytocin plus thapsigargin and (d) FDA 2 mg/ml
FDA administration with and without the presence of 2-APB and
tration in the FDA treated group while thapsigargin caused a slight
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crease in the number of these uterotonin receptors, po-
tentiating the effect of FDA on uterine contraction.
There is a possibility that the greatest effect produced
following FDA binding to the oxytocin receptor (as evi-
denced by the greatest inhibition of the Emax by atosiban)
was due to high number of this receptor expression in
the uterus. Meanwhile, lesser inhibition by THG113.31
and atropine suggested that the number of PGF2α and
muscarinic receptors expressed was lower than the num-
ber of oxytocin receptor expression. Up-regulation of oxy-
tocin receptor by E2 and at term [26,27] has been reported
in human [28], rat [25] and mouse [29] uterus while
muscarinic and PGF2α receptors expression has also
been reported in rat [30-33], rabbit [34] and human [23]
uterus which were also being up-regulated by E2 [24].
Previous reports also indicate that oxytocin receptor ex-
pression in the uterus is the highest [35,36], supporting
our observation that FDA effect was mostly mediated
via this receptor binding. Apart from the increase in the
number of receptors, high affinity FDA binding to the
oxytocin receptor may also result in the observed effect.
Oxytocin and PGF2α have been reported to play an
important role in the myometrial contraction [37].
Oxytocin-induced myometrial contraction has been shown
in estrogen-primed non-pregnant swine uteri [38,39]. Acti-
vation of the oxytocin and PGF2α receptors which are
coupled to G protein alpha(q) stimulates uterine con-
traction through activating the phospholipase C/Ca2+
dependent pathway, while activation of the muscarinic
receptor which is coupled to G protein alpha(i) potenti-
ates contraction through inhibiting the cAMP produc-
tion [40]. Besides Ficus deltoidea, other Ficus species
including Ficus asperifolia has also been reported to
induce uterine contraction through binding to the
muscarinic, oxytocin and histamine receptors in the
uterus [41].
Ca2+, which is essential for smooth muscle contraction
[42], can be derived from the intracellular stores and/or
extracellular fluid [42,43]. Extracellular Ca2+ enters the
cell via the voltage-gated dihydropyridine channels at the
myocyte plasma membrane [44]. Following the opening
of this channel, Ca2+ enters down its concentration gra-
dient. This will then trigger the release of Ca2+ from the
intracellular stores [45]. In this study, the involvement
of intracellular and extracellular Ca2+ in myometrial
contraction was investigated following oxytocin and
2 mg/ml FDA administration. Our findings indicate that
oxytocin-induced uterine contraction depends mostly
on the extracellular Ca2+ while intracellular Ca2+ is also
required for contraction. Following binding of oxytocin
to its G protein-coupled receptor, phospholipase C (PLC)
will be activated which causes an increase in inositol
trisphosphate (IP3) and diacylglycerol (DAG) levels. IP3activates the IP3R receptor at the sarcoplasmic reticulum
membrane which causes the release of stored Ca2+ into
the cytosol. Increased cytosolic Ca2+ will further induced
extracellular Ca2+ influx [42], resulting in a further rise
in the intracellular Ca2+ level. Ca2+ will then binds to
calmodulin, which activates the myosin light chain kin-
ase leading to phosphorylation of myosin light chains,
triggering contraction [46].
A marked decrease in the Emax following oxodipine
and EDTA administration suggested the dependency of
FDA-induced uterine contraction on the extracellular
Ca2+. This could be similar to the contraction induced
by wild ginger (Costus speciosus) rhizome [47] and pom-
egranate (Punica granatum L., Punicaceae) seed [48] ex-
tracts which was also shown to solely depend on the
extracellular Ca2+. In this study, FDA binding to the
muscarinic, oxytocin and PGF2α receptors may trigger
the extracellular Ca2+ influx prior to contraction. Although
FDA has been shown to mediate its uterotonic effect,
mostly via oxytocin receptor binding, the contraction
produced however does not depend on the intracellular
Ca2+ as evident from the lack of inhibition on the Emax
by 2-APB. This is in contrast to oxytocin-induced uter-
ine contraction, whereby its dependency on the intracel-
lular Ca2+ was evidenced from the inhibition of Emax
by 2-APB. We speculated that the inability of FDA to
induce the release of Ca2+ from the internal stores could
be due to its inability to provide adequate stimulus to
trigger the intracellular cascade leading to the release of
Ca2+ from the intracellular stores, despite of its binding
to the oxytocin receptor. On the other hand, FDA may
also bind at lower affinity to other uterotonin receptors,
which may explain lesser potency of FDA as uterotonin
as compared to oxytocin, PGF2α and Ach.
In addition to the binding to the oxytocin receptor,
FDA-induced extracellular Ca2+ influx could also involve
other agonists’ receptor binding. This includes the PGF2α
receptor; which was found to mediate uterine contraction
in the laying hens via inducing the influx of extracellular
Ca2+ [49]. Our finding has shown that administration
of thapsigargin, a SERCA inhibitor resulted in a slight
but significant increase in the Emax induced by oxyto-
cin and FDA. This effect could be due to the depletion
of stored Ca2+ by thapsigargin which inhibit the re-
uptake of cytosolic Ca2+ into the sarcoplasmic reticulum.
The consistently high cytosolic Ca2+ will activate extra-
cellular Ca2+ entry which would further enhance uterine
smooth muscle contraction [50].
Conclusion
Using in-vitro model, our study has provided the first
scientific evidence to support the claim that Ficus deltoi-
dea stimulates uterine contraction. The active compound
that is responsible in mediating this effect is currently
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contain flavonoids isovitexin, vitexin [51], proantrocyani-
dins, flavan-3-ol monomer and flavones glycosides [52].
Phytochemical analyses further revealed the presence of
tannins, tripterpenoids and phenols although alkaloids
and steroids were not commonly found [10]. This
in-vitro study using isolated rodent’s uteri therefore
provides preliminary evidence which could be used to
further explore the in-vivo effect of this plant compound
on uterine contraction.
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